<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0007115" disease_type="Neoplastic Process" abbrv="">Thyroid cancer</z:e> 1 (TC-1, C8orf4) is involved in the development of many <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we investigated the correlation between the expression of TC-1 and the clinicopathological characteristics of ovarian and colorectal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We also explored the possible use of TC-1 as a marker to distinguish between <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic tumors</z:e> of the ovary and colorectum </plain></SENT>
<SENT sid="3" pm="."><plain>We used immunohistochemistry to examine the expression level of TC-1 in 100 ovarian and 100 colorectal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> and 25 metastatic <z:mp ids='MP_0002038'>carcinomas</z:mp> with the ovary or colorectum as primary site </plain></SENT>
<SENT sid="4" pm="."><plain>TC-1 was expressed in <z:hpo ids='HP_0000001'>all</z:hpo> <z:mp ids='MP_0003579'>ovarian carcinoma</z:mp> samples </plain></SENT>
<SENT sid="5" pm="."><plain>The high expression rate of TC-1 was 84 % in <z:mp ids='MP_0003579'>ovarian carcinomas</z:mp>, which was much higher than that observed in colorectal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> (35 %, P &lt; 0.001) </plain></SENT>
<SENT sid="6" pm="."><plain>High expression of TC-1 significantly correlated with poor differentiation of <z:mp ids='MP_0003579'>ovarian carcinomas</z:mp> (P = 0.013) </plain></SENT>
<SENT sid="7" pm="."><plain>To explore the value of TC-1 in distinguishing <z:e sem="disease" ids="C0278688" disease_type="Neoplastic Process" abbrv="">metastatic ovarian cancers</z:e> from <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e>, we found the area under the receiver operator characteristic curve of TC-1 to be 0.819 (95 % confidence interval, 0.760-0.878; P &lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Furthermore, TC-1 was highly expressed in 100 % of nine <z:e sem="disease" ids="C0278688" disease_type="Neoplastic Process" abbrv="">metastatic ovarian cancers</z:e>, but only in 31 % of 16 metastatic <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The higher expression of TC-1 in ovarian compared to colorectal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> suggests its potential use as a marker, to distinguish between metastatic ovarian and colorectal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
</text></document>